10Jan 2024
Cellectar's blood cancer therapy succeeds in late-stage study

Cellectar's blood cancer therapy succeeds in late-stage study

Cellectar Biosciences announced on Monday that its therapy for Waldenstrom's macroglobulinemia (WM), a rare blood cancer, achieved its primary goal in a late-stage study. In the trial, 75.6% of WM patients experienced a reduction in cancer size or its disappearance with Cellectar's iopofosine. Additionally, 76% of those who completed the four-dose therapy remained progression-free for an average of eight months. The New Jersey-based company plans to seek accelerated FDA approval for iopofosine, aiming for a potential mid-2025 launch.

  • #family health

Like

Save

Share